ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 209

Joint Overuse in Patients with Rheumatoid Arthritis

Daisuke Kobayashi1, Sachimi Amao 2, Satoshi Ito 3, Kiyoshi Nakazono 3, Hajime Ishikawa 4 and Ichiei Narita 1, 1Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Niigata, Japan, 2Nursing department, Niigata Rheumatic Center, Shibata, Japan, 3Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan, 4Department of Rheumatology, Niigata Rheumatic Center, Shibata, Niigata, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Education, patient, rehabilitation and activities of daily living (ADL), Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Epidemiology & Public Health Poster I: RA – ARP

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The development of drug therapies for rheumatoid arthritis (RA), and control of synovitis has now become easier. However, once patients are relieved of pain, they become physically more active and sometimes overuse their joints. Such overuse can result in progression of joint deformity, joint destruction, and in some cases, tendon rupture. However, the actual situation of joint overuse in RA patients remains insufficiently recognized. Here we analyzed the clinical characteristics of such patients who had overused their joints.

Methods: In-depth history taking about joint overuse and physical examinations were performed prospectively for 3148 consecutive patients with RA who visited our outpatient department between August 2016 and October 2016. The patients who satisfied the following inclusion criteria were diagnosed as having joint overuse: (i) met the 2010 American College of Rheumatology/European League against Rheumatism criteria for RA, (ii) had experienced preceding events that exerted a strain on the joints, and (iii) had joint pain and/or swelling of the strained joints. Patients who were suspected of having other conditions such as infection, trauma, pseudogout, and gout were excluded. Among the patients, 41 (10 men and 31 women) were diagnosed as having joint overuse. The patients’ clinical features and laboratory data before they developed joint overuse were collected from their medical records. As comparative controls, we selected 123 age- and sex-matched contemporary patients with RA who had no joint overuse from among 3148 patients. Comparisons between the parameters at different time points were performed using the Friedman test, and a post hoc analysis was performed using the Wilcoxon signed-rank test with Holm correction. The data were expressed as median (interquartile range).

Results: Forty-one patients with a mean age of 62.0 years (range, 54.0–69.0 years) were diagnosed as having joint overuse. The different joints affected by overuse were the wrist (16), hand (thumb and fingers, n = 12), shoulder (4), knee (3), ankle (3), and forefoot (3). The reasons for overuse were occupational in 25 patients, housework in 10, hobbies in 5, and ceremonial occasions in 1. The clinical disease activity index at baseline was 5.00 (2.60–9.00), which increased to 9.00 (6.00–11.3) owing to overuse, and improved to 4.80 (2.20–9.00) at the next visit (p < 0.001 and p < 0.001, respectively). The 28-joint Disease Activity Score based on erythrocyte sedimentation rate, C-reactive protein, visual analog scale score for pain, and swollen joint count was also elevated transiently. Logistic regression analysis revealed that treatment with biological disease-modifying antirheumatic drugs (bDMARDs; odds ratio [OR], 3.28; 95% confidence interval [CI], 11.32–8.17), low health assessment questionnaire disability index (HAQ-DI; OR, 0.301; 95% CI, 0.11–0.85), and Steinbrocker stage III or IV (OR, 6.89; 95% CI, 2.57–18.5) were significantly associated with the development of joint overuse.

Conclusion: When patients with advanced RA have low HAQ-DI using bDMARDs, they are at risk of joint overuse. Appropriate education would be important for such patients to prevent the overuse.


Disclosure: D. Kobayashi, None; S. Amao, None; S. Ito, None; K. Nakazono, None; H. Ishikawa, None; I. Narita, None.

To cite this abstract in AMA style:

Kobayashi D, Amao S, Ito S, Nakazono K, Ishikawa H, Narita I. Joint Overuse in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/joint-overuse-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/joint-overuse-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology